Increased expression of macrophage inflammatory protein-1a on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma The biology of bone destruction in multiple myeloma (MM) includes an increased activity of osteoclasts, which is accompanied by a reduction in osteoblast function leading to a high resorptive phase and subsequent bone loss. Macrophage inflammatory protein-1a (MIP-1a) is a low-molecular-weight chemokine that belongs to the regulated upon activation, normal T-cellexpressed and presumably secreted (RANTES) family. MIP-1a is produced by myeloma cells and enhances osteoclast activity in the myeloma microenvironment, acting on differentiated osteoclasts in a dose-dependent manner. 1 Earlier studies have shown that MIP-1a levels are elevated in the bone marrow plasma and the serum of patients with MM, whereas serum MIP-1a and the gene expression of MIP-1a correlate with the presence of lytic lesions in MM. 2, 3 MIP-1a is a chemoattractant for monocytes and recently it was shown that monocytes may give rise to vascular endothelium. 4 Thus, our hypothesis was that myeloma cells express MIP-1a and other chemoattractants for monocytes and macrophages, and this expression correlated with both increased bone resorption (as osteoclasts are originated from a macrophage lineage precursor cell) and increased angiogenesis. The aim of our study was to evaluate the role of MIP-1a immunoexpression on trephine biopsies in the development of myeloma bone disease and examine possible correlations between MIP-1a expression and clinical data, including prognostic factors of MM and angiogenesis.
Patients with newly diagnosed MM having a bone marrow trephine biopsy before any kind of anti-myeloma therapy administration, including bisphosphonates and steroids, were eligible for participating in the study. Evidence of bone involvement at the time of diagnosis was documented using plain radiography. A grading of bone morbidity into three groups according to the radiographic evaluation of the skeleton was made. Group A included patients with no lytic lesions, group B included patients with osteolytic lesions in 1-3 areas and group C included patients with lytic lesions in more than three areas and/or a pathological fracture due to MM. The study was conducted after obtaining an approval from the Ethics Committee/Institutional Review Board and an informed consent was obtained from all patients before any intervention.
Bone marrow trephine was paraffin embedded and decalcified with a low pH EDTA buffer (EDTA-HCL). Immunochemistry staining was performed in an automatic instrument (XT Benchmark, Ventana, Tucson, AZ, USA) using an anti-MIP-1a monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the dilution was 1:20. The immunoreactivity of MIP-1a was examined on the basis of positive plasma cells (PCs) with the following cutoff values: o20% positive PCs (negative group, group I), 20-50% positive PCs (intermediate expression group, group II) and 450% positive PCs (high expression group, group III). MIP-1a expression was also evaluated in 10 patients with monoclonal gammopathy of undetermined significance (MGUS). An immunochemical identification of microvascular endothelial cells was also performed in the above bone marrow specimens with a human monoclonal antibody against CD34 (DAKO A/S, Glostrup, Denmark) and VEGF (DAKO A/S, Glostrup, Denmark) by two experienced pathologists at Â 400 magnification, as described earlier. 5 In each biopsy sample, microvessels were counted in at least three independent hot spots per section and the microvessel density (MVD) of a bone marrow specimen was calculated as the mean value of all independent readings and recorded as the number of microvessels per Â 400 field. When the microvessel count was 1-2, angiogenesis was characterized to be of low grade, whereas intermediate-grade angiogenesis was defined by the presence of a microvessel count of 3-6 and high-grade angiogenesis by the presence of a microvessel count of X7. MVD was also evaluated in the aforementioned 10 MGUS patients. On the day of trephine biopsy, fasting blood samples were taken and serum was separated within 4 h and stored at À70 1C until the day of measurement. Using ELISA (enzyme-linked immunosorbent assay) methodology, we measured the following in the patients' serum: (i) MIP-1a (R&D Systems, Minneapolis, MN, USA); (ii) C-terminal crosslinking telopeptide of collagen type I (CTX; Serum Crosslaps, Nordic Bioscience Diagnostics, Boldon, Tyne & Wear, UK); and (iii) bone-specific alkaline phosphatase (bALP; Metra BAP/Quidel, San Diego, CA, USA), according to the manufacturers' instructions. Serum MIP-1a, CTX and bALP were also evaluated in 20 healthy controls (10 male/10 female) with a median age of 67.5 years (range: 45-78 years). Each control was examined to ensure that there was no evidence of bone disease (osteoporosis or osteoarthritis), no receipt of medication that could alter the normal bone turnover during the last 6 months and no evidence of infection or autoimmune disease on the day of sampling.
Differences between patients and controls were evaluated using the Mann-Whitney test. The association between extent of bone disease or stage and MIP-1a was examined using ANOVA (analysis of variance). The Spearman's rank correlation test was used to examine correlations between various parameters. Survival probabilities were calculated by the Kaplan-Meier method and comparisons were made using the log-rank test to identify potential prognostic factors.
A total of 130 patients with newly diagnosed MM, who were diagnosed, treated and followed-up in a single center between 1999 and 2007, were studied. Clinical characteristics of the patients are depicted in Table 1 . The immunostaining for MIP-1a in the trephine biopsies revealed that 37 (28%) patients had a negative (o20%) MIP-1a expression (group I), whereas 17 (13%) showed intermediate positivity (group II) and 79 (59%) had high MIP-1a positivity on their PCs (group III; Figures 1a-c). All MGUS patients had a very low percentage of positive PCs for MIP-1a expression (o10%, negative group; median 6%; range 0-10%; Po0.0001 compared with MM patients; Figure 1d ). On the basis of MVD measurements, 55 patients (42%) had lowgrade angiogenesis, whereas 37 patients (28%) had intermediategrade and 38 patients (30%) had high-grade angiogenesis. All patients with MGUS and asymptomatic MM had low-grade angiogenesis. There was a significant correlation between the MIP-1a expression on marrow PCs and MVD measurement (ANOVA P ¼ 0.015; Figure 2a ).
Newly diagnosed patients with MM had elevated serum MIP-1a than did healthy controls (median (range) for patients and controls were 22 pg/ml (2.1-135 pg/ml) vs 14 pg/ml (0.02-54 pg/ml), respectively; Po0.0001). More specifically, 91 patients (70%) had a MIP-1a serum level value 414 pg/ml, which was the median value observed in the controls. There was a strong correlation between serum MIP-1a and the MIP-1a expression on PCs in biopsies (r ¼ 0.32, Po0.001). Patients also had increased CTX (median (range) for patients and controls: 0.96 ng/ml (0.32-2.93 ng/ml) vs 0.41 ng/ml (0.12-0.81 ng/ml), respectively; Po0.001) and a borderline reduction of bALP (20.9 U/l (3.8-45.2 U/l) vs 24.4 U/l (18.3-44.6 U/l), respectively; P ¼ 0.078).
The MIP-1a expression significantly correlated with the extent of bone disease. The median percentage values (range) of MIP-1a-positive PCs in trephine biopsies was 10 (5-35%), 40 (18-60%) and 90% (70-100%) for patients with bone disease of grade A, B and C, respectively (ANOVA Po0.0001; Figure 2b ). More specifically, 64 of 87 patients with osteolytic lesions (73.5%) had at least an intermediate expression of MIP-1a on the PCs of their trephine biopsy, whereas 57 of 96 patients (59%) with an intermediate or high expression of MIP-1a in the trephine biopsies 
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were classified into group C in terms of the extent of bone disease. Receiver operating characteristic (ROC) curve analysis identifies a cutoff of 32.5% of positive PCs for MIP-1a in the trephine biopsy as being 92% sensitive for the presence of osteolytic lesions in the skeletal survey (B or C grade of bone disease), whereas the specificity of the same value of MIP-1a-positive PCs for the presence of lytic lesions was 95.2%. Furthermore, MIP-1a expression significantly correlated with serum CTX (Po0.0001), but not with serum bALP (P ¼ 0.182). Serum MIP-1a also correlated with the extent of MM bone disease (Figure 2c ). Serum MIP-1a correlated with serum CTX (r ¼ 0.312, Po0.01), but not with serum bALP (r ¼ À0.192, P ¼ 0.128).
Patients with International Staging System (ISS) 3 disease had an increased MIP-1a expression (median MIP-1a-positive PCs 60%, range: 20-100%) compared with patients with stage 1 (median 35%, range: 5-100%; P ¼ 0.03) and stage 2 disease (median 45%, range: 5-100%; P ¼ 0.04). Similarly, serum MIP-1a was increased in ISS 3 MM (median 36 pg/ml, range: 10-83 pg/ml) compared with that in ISS 1 (median 21 pg/ml, range: 2-56 pg/ml; P ¼ 0.029) and in ISS 2 MM (median 19 pg/ml, range: 3-82 pg/ml; P ¼ 0.035). The increased immunoexpression of MIP-1a correlated also with low platelet count (r ¼ 0.282, P ¼ 0.0012), hypercalcemia (r ¼ 0.246, P ¼ 0.022), elevated serum creatinine (X2 mg per 100 ml; r ¼ 0.258, P ¼ 0.027) and PC infiltration on marrow biopsy (r ¼ 0.348, Po0.0001).
The median follow-up period of the patients was 30 months (range: 4-108 months). The median overall survival was 48 months (range 10-72 months) and the median progression-free survival was 14 months (range: 2-47 months). Patients with asymptomatic MM were not included in the survival analysis. Neither the MIP-1a expression on PCs in biopsies nor serum MIP-1a correlated with overall survival or progression-free survival (Table 1) .
In our study, we observed an increased (intermediate or high) PC expression of MIP-1a in the marrow biopsies of 93 (72%) of 130 earlier untreated MM patients. Furthermore, almost 60% of these patients had extended bone disease (grade C). Uneda et al. 6 have shown that 58% of MM patients expressed MIP-1a mRNA and suggested that the expression of mRNA may contribute to the development of bone lesions, irrespective of the serum levels of the protein. We observed that both the expression of MIP-1a on trephine biopsies and serum MIP-1a strongly correlated with the extent of lytic bone disease and bone resorption marker CTX, confirming the significant role of MIP-1a in the biology of bone destruction in MM. However, although the MIP-1a expression on PCs of trephine biopsies could separate three groups of patients who had significant differences in terms of severity of bone disease (Figure 2a) , serum MIP-1a could only separate patients with regard to the presence of lytic lesions on plain radiography (Figure 2c ). This result supports the hypothesis that bone destruction is mainly a local process, but high levels of MIP-1a can be achieved and detected in the serum if bone disease is sufficiently severe. 2 In this study, correlations between an increased MIP-1a expression in trephine biopsies and advanced myeloma were observed. Patients with ISS 3 MM had almost a 1.5-fold higher percentage of positive PCs for MIP-1a in marrow biopsy and almost threefold higher median values of serum MIP-1a. The correlation of MIP-1a with advanced disease suggests that there is a significant role of MIP-1a in the biology of myeloma, which can be explained by its impact on plasma cell accumulation, proliferation and growth. A recent study has additionally suggested that the increased production of MIP-1a by myeloma cells further enhances myeloma cell binding to stromal cells by the stimulation of very late antigen-4 (VLA4)-vascular cell adhesion molecule-1 (VCAM1) adhesion, forming a 'vicious cycle' between MM cell adhesion to stromal cells and MIP-1a production through VLA4-VCAM1 interaction. 7 Furthermore, blocking of the MIP-1a expression in myeloma cells injected into severe immunodeficient mice or treating the animals with a neutralizing antibody to MIP-1a resulted not only in a significant reduction of bone lesions but also in a significant reduction of serum paraprotein. 8 Despite the strong correlation of MIP-1a with MM severity, we did not find any predictive value of MIP-1a for survival. In an earlier study of our group, patients with high serum MIP-1a had a poor prognosis. 2 However, this was the result of the univariate analysis that was not confirmed by the multivariate models. 2 Furthermore, in that study, all patients had received conventional chemotherapy. On the contrary, in this study, 29 of 115 (25%) patients with symptomatic MM received bortezomibbased regimens and 31 (26%) received thalidomide-based regimens as first line therapy, whereas all these patients received regimens containing bortezomib or an immunomodulatory drug at some point during the course of their MM. Both bortezomib and immunomodulatory drugs alter the interactions between MM cells and the microenvironment and improve survival in MM. The lack of correlation between MIP-1a and survival may also be because of a possible overriding of the negative effect of the MIP-1a pathway by novel agents.
Another interesting observation of our study was the strong correlation between MVD and the MIP-1a expression on PCs. During the last few years, there is increased evidence for the presence of a close link between MM cells, osteoclasts and vascular endothelial cells to form a vicious cycle between bone destruction, angiogenesis and myeloma expansion. Monocytes, macrophage precursors and mast cells seem to have a significant role in this cycle. Recent data support the fact that monocytes induce vascular endothelial cell gene expression and develop tube-like structures when they are exposed to serum or cultured with bone marrow from MM patients. Furthermore, when co-injected with human MM cells into SCID (severe combined immunodeficiency) mice, human monocytes were incorporated into tumor blood vessels and expressed human vascular endothelial protein markers and genes. 4 A number of myeloma-derived chemo-attractants seem to ensure the ongoing recruitment of macrophages and monocytes that accumulate in hypoxic marrow areas, including M-CSF, VEGF and the CC-chemokines: MIP-1a, MCP-1a and others. Thus, the increased MIP-1a expression by PCs observed in our study may contribute to increased angiogenesis through the chemoattraction of such monocytes. Although this is a hypothesis, it might explain the strong correlation between marrow MVD and the MIP-1a expression on PCs of MM patients.
In conclusion, our findings underline, for the first time, the frequent expression of MIP-1a in MM patients and the correlations between the expression of MIP-1a on PCs and advanced myeloma, extensive lytic disease and increased angiogenesis. These results are consistent with the important role of MIP-1a not only in the development of bone destruction in MM but also in the biology of myeloma cell growth, and reveal MIP-1a as a possible therapeutic target. Multiple myeloma is a plasma cell neoplasm that results in 14 000 deaths per year in the United States. 1 Although most patients initially responded to standard treatments over the last 30 years, the development of multidrug resistance was common and left few therapeutic options for patients with refractory disease. Therefore, newer therapeutic strategies needed to be identified for more effective treatment of the disease. Bortezomib was tested in refractory myeloma and displayed significant activity as a single agent.
Bortezomib is the first in a class agent that functions by inhibiting the proteasome. The initial success of bortezomib has provided the rationale for the development of additional proteasome inhibitors such as carfilzomib and NPI-0052 that are currently in clinical trials. 2 The success of bortezomib and the expanded use of proteasome inhibitors to include the treatment of newly diagnosed patients will likely result in the acquired resistance to this class of agents. Therefore, we set out to determine the nature of the acquired resistance to a proteasome inhibitor.
To determine factors associated with acquired resistance to proteasome inhibitors we developed KMS11R. We selected cells with the proteasome inhibitor, epoxomicin, for several reasons. It inhibits the same activity of the proteasome as bortezomib, namely the chymotryptic activity found in the b5 subunit. 3 However, epoxomicin is an irreversible inhibitor whereas bortezomib is reversible; therefore, selection would be easier and require less drug. In addition, carfilzomib, a proteasome inhibitor in clinical trials for the treatment of multiple myeloma, is derived from epoxomicin. 4 KMS11R did not display overt changes phenotypically as the cells maintained expression of surface CD138 as well as FGFR3 (not shown). However, the cells became resistant to epoxomicin at concentrations that are 10 times greater than the initial selecting concentration (2 nM). As seen in Figure 1a KMS11 cells display a dose-dependent 
